Evidence map›Paper›PMID 40569897›Full record

Observational studyJournal of the International AIDS Society2025

Limited awareness and use of HIV post-exposure prophylaxis among people vulnerable to HIV acquisition in Western Kenya: a cross-sectional analysis.

Glenna Schluck, Matthew L Romo, Josphat Kosgei, Michael C Thigpen, Natalie Burns, Rael Bor, Deborah Langat, Christine Akoth, Adam Yates, Curtisha Charles and 6 more

Abstract readObservational Study
In one paragraph

Observational study in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. HIV Post Exposure Prophylaxis: prospects, opportunities and challenges.Journal of the International AIDS Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Glenna SchluckHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-5311-9636
Matthew L RomoHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-3038-0644
Josphat KosgeiU.S. Military HIV Research Program, Walter Reed Army Institute of Research - Africa, Kericho, Kenya.
Michael C ThigpenU.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Natalie BurnsHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Rael BorU.S. Military HIV Research Program, Walter Reed Army Institute of Research - Africa, Kericho, Kenya.
Deborah LangatU.S. Military HIV Research Program, Walter Reed Army Institute of Research - Africa, Kericho, Kenya.
Christine AkothU.S. Military HIV Research Program, Walter Reed Army Institute of Research - Africa, Kericho, Kenya.
Adam YatesHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Curtisha CharlesHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Haoyu QianHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Britt GayleHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Margaret YacovoneNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Fredrick SaweU.S. Military HIV Research Program, Walter Reed Army Institute of Research - Africa, Kericho, Kenya.
Trevor A CrowellHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-5947-265X
Multinational Observational Cohort of HIV and other Infections (MOCHI) Study Group

Funding

HIV Vaccine Research and Development - Central Nervous System StudiesAAI20052001 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI AKE, JULIE · 2020 to 2020
$22.9M
NIAID NIH HHS AAI20052001U.S. Department of Defense HT9425-24-3-0004U.S. Department of Defense W81XWH-18-2-0040
6 · The paper itself

Abstract

introductionHIV post-exposure prophylaxis (PEP) can prevent HIV acquisition and facilitates linkage to pre-exposure prophylaxis (PrEP) for people with ongoing vulnerability. We assessed PEP awareness and use in Western Kenya.

methodsWe used cross-sectional screening/enrolment data from the Multinational Observational Cohort of HIV and other Infections (MOCHI) study. Eligible participants had behavioural vulnerability to HIV and were ages 14-55 years. Participants completed questionnaires on demographics, sexual/behavioural history, and PEP/PrEP awareness and use. Depression was assessed using the Patient Health Questionnaire (PHQ-9) with none/minimal, mild and moderate/severe depression defined as PHQ-9 scores of 0-4, 5-9 and ≥10, respectively. We used multivariable robust Poisson regression with purposeful variable selection to estimate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) for factors associated with PEP awareness.

resultsFrom December 2021 to May 2023, 398 participants indicated whether they heard of PEP. The median age was 22 years (IQR 19-24), 316/399 (79.2%) were female and 315/389 (81.0%) reported sex work or transactional sex. One hundred fourteen (28.6%) participants had never heard of PEP, of whom 79 (69.3%) had also not heard of PrEP. Among 284 participants who had heard of PEP, 74 (26.1%) did not know where to access it. Seventy-one participants (17.8%) had taken PEP, of whom 17 (23.9%) encountered problems accessing PEP such as unavailability (n = 5) or prohibitive expense (n = 4). In the final model, only <12 years of education (aPR 1.65 [95% CI 1.16-2.34]) and not cohabitating (aPR 2.81 [95% CI = 1.11-7.08]) were associated with never having heard of PEP. Among participants who had heard of PEP, factors associated with not knowing where to access PEP were <12 years of education (aPR 2.20 [95% CI 1.37-3.54]) and depression (mild aPR 1.86 [95% CI 1.17-2.96]; moderate/severe aPR 1.84 [95% CI 1.09-3.09], compared to none/minimal).

conclusionsDespite enrolling a behaviourally vulnerable group potentially eligible for PEP, we identified substantial gaps in PEP awareness, access and use. Demand generation and improved access to PEP are needed to maximize the impact on reducing HIV incidence. Interventions to improve PEP awareness and access may be most impactful for people with lower education or when coupled with mental health services.

Indexed as

Health Knowledge, Attitudes, PracticeHIV InfectionsPost-Exposure ProphylaxisAdolescentAdultCross-Sectional StudiesFemaleHumansKenyaMaleMiddle AgedPre-Exposure ProphylaxisSurveys and QuestionnairesYoung Adulthealth risk behavioursHIVimplementation sciencepost‐exposure prophylaxispre‐exposure prophylaxissexually transmitted infection

Identifiers

PMID40569897
PMCPMC12231640

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.